drugset
Drugs / MAT2203
last change Jul 2026 re-read 3 minutes ago

MAT2203

also known as cAMB
Developed for
Cryptococcal meningitis
Investigated by
Matinas BioPharma Nanotechnologies, Inc. · University of Minnesota

Trials 2

today NCT05541107 · Ph 3 NCT04031833 · Ph 1/2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial · 1 met primary
Phase 1/2 NCT04031833 Oct 2019 → Nov 2022 Cryptococcal meningitis Matinas BioPharma Nanotechnologies, Inc. Completed Met primary
Phase 31 trial
Phase 3 NCT05541107 Jan 2023 → Oct 2024 Cryptococcal meningitis Matinas BioPharma Nanotechnologies, Inc. Unknown No outcome recorded

Press releases naming this drug 46 releases

DateIssuerRelease
2026-07-13 Matinas BioPharma Nanotechnologies, Inc. Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals matinasbiopharma.com ↗
2024-10-31 Matinas BioPharma Nanotechnologies, Inc. Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction matinasbiopharma.com ↗
2024-06-24 Matinas BioPharma Nanotechnologies, Inc. Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program matinasbiopharma.com ↗
2024-06-13 Matinas BioPharma Nanotechnologies, Inc. Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin matinasbiopharma.com ↗
2024-04-30 Matinas BioPharma Nanotechnologies, Inc. In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy matinasbiopharma.com ↗
2024-03-22 Matinas BioPharma Nanotechnologies, Inc. Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response matinasbiopharma.com ↗
2024-02-26 Matinas BioPharma Nanotechnologies, Inc. Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution matinasbiopharma.com ↗
2024-02-20 Matinas BioPharma Nanotechnologies, Inc. Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis matinasbiopharma.com ↗
2023-12-21 Matinas BioPharma Nanotechnologies, Inc. Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA matinasbiopharma.com ↗
2023-10-11 Matinas BioPharma Nanotechnologies, Inc. Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution matinasbiopharma.com ↗
2023-09-27 Matinas BioPharma Nanotechnologies, Inc. Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek matinasbiopharma.com ↗
2023-08-22 Matinas BioPharma Nanotechnologies, Inc. Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases matinasbiopharma.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MAT2203 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05541107 ↗
1

NCT04031833 ↗
Known as cAMB “MAT2203 or encochleated oral amphotericin B (cAMB) is a lipid nano-crystal formulation designed for targeted oral delivery of the antifungal drug AMB for treatment of fungal...” NCT04031833 ↗
Route Oral “designed for targeted oral delivery of the antifungal drug AMB” NCT04031833 ↗